The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells
Open accessAbstract
Introduction: The ability to self-renew, be easily expanded in vitro and differentiate into different mesenchymal tissues, render mesenchymal stem cells (MSCs) an attractive therapeutic method for degenerative diseases. The subsequent discovery of their immunosuppressive ability encouraged clinical trials in graft-versus-host disease and auto-immune diseases. Despite sharing several immunophenotypic characteristics and functional capabilities, the differences between MSCs arising from different tissues are still unclear and the published data are conflicting. Methods: Here, we evaluate the influence of human MSCs derived from umbilical cord matrix (UCM), bone marrow (BM) and adipose tissue (AT), co-cultured with phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (MNC), on T, B and natural killer (NK) cell activation; T and B cells’ ability to acquire lymphoblast characteristics; mRNA expression of interleukin-2 (IL-2), forkhead box P3 (FoxP3), T-bet and GATA binding protein 3 (GATA3), on purified T cells, and tumor necrosis factor-alpha (TNF-α), perforin and granzyme B on purified NK cells. Results: MSCs derived from all three tissues were able to prevent CD4+ and CD8+ T cell activation and acquisition of lymphoblast characteristics and CD56 dim NK cell activation, wherein AT-MSCs showed a stronger inhibitory effect. Moreover, AT-MSCs blocked the T cell activation process in an earlier phase than BM- or UCM-MSCs, yielding a greater proportion of T cells in the non-activated state. Concerning B cells and CD56 bright NK cells, UCM-MSCs did not influence either their activation kinetics or PHA-induced lymphoblast characteristics, conversely to BM- and AT-MSCs which displayed an inhibitory effect. Besides, when co-cultured with PHA-stimulated MNC, MSCs seem to promote Treg and Th1 polarization, estimated by the increased expression of FoxP3 and T-bet mRNA within purified activated T cells, and to reduce TNF-α and perforin production by activated NK cells. Conclusions: Overall, UCM-, BM- and AT-derived MSCs hamper T cell, B cell and NK cell-mediated immune response by preventing their acquisition of lymphoblast characteristics, activation and changing the expression profile of proteins with an important role in immune function, except UCM-MSCs showed no inhibitory effect on B cells under these experimental conditions. Despite the similarities between the three types of MSCs evaluated, we detect important differences that should be taken into account when choosing the MSC source for research or therapeutic purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Chamberlain, G., Fox, J., Ashton, B., & Middleton, J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0197 · Cited by 2,381
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt
Potten, C. S., & Loeffler, M. (1990) · Development · doi:10.1242/dev.110.4.1001 · Cited by 1,791
Immunomodulatory properties of mesenchymal stromal cells
Nauta, A. J., & Fibbe, W. E. (2007) · Blood · doi:10.1182/blood-2007-02-069716 · Cited by 1,788
Human mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
Krampera, M., Glennie, S., Dyson, J., Scott, D., Laylor, R., Simpson, E., & Dazzi, F. (2003) · Blood · doi:10.1182/blood-2002-07-2104 · Cited by 1,598
Tse, W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C., & Guinan, E. C. (2003) · Transplantation · doi:10.1097/01.tp.0000045055.63901.a9 · Cited by 1,500
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy
Zappia, E., Casazza, S., Pedemonte, E., Benvenuto, F., Bonanni, I., Gerdoni, E., Giunti, D., Ceravolo, A., Cazzanti, F., Frassoni, F., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1496 · Cited by 1,430
CD4 + T Cells: Differentiation and Functions
Luckheeram, R. V., Zhou, R., Verma, A. D., & Xia, B. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/925135 · Cited by 1,381
Spaggiari, G. M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2008) · Blood · doi:10.1182/blood-2007-02-074997 · Cited by 1,146
Adipose-derived adult stem cells: isolation, characterization, and differentiation potential
Gimble, J. M., & Guilak, F. (2003) · Cytotherapy · doi:10.1080/14653240310003026 · Cited by 1,104
Selmani, Z., Naji, A., Zidi, I., Favier, B., Gaiffe, E., Obert, L., Borg, C., Saas, P., Tiberghien, P., Rouas-Freiss, N., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0554 · Cited by 1,081
Kolf, C. M., Cho, E., & Tuan, R. S. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2116 · Cited by 970
Interactions Between Human Mesenchymal Stem Cells and Natural Killer Cells
Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006) · Stem Cells · doi:10.1634/stemcells.2004-0359 · Cited by 956
Mesenchymal Stromal Cells: Current Understanding and Clinical Status
Salem, H. K., & Thiemermann, C. (2010) · Stem Cells · doi:10.1002/stem.269 · Cited by 915
Ding, D.-C., Shyu, W.-C., & Lin, S.-Z. (2011) · Cell Transplantation · doi:10.3727/096368910x · Cited by 894
Mesenchymal Stem Cells: Mechanisms of Inflammation
Singer, N. G., & Caplan, A. I. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130230 · Cited by 851
Mesenchymal stem cells avoid allogeneic rejection
Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005) · Journal of Inflammation · doi:10.1186/1476-9255-2-8 · Cited by 714
Augello, A., Tasso, R., Negrini, S. M., Amateis, A., Indiveri, F., Cancedda, R., & Pennesi, G. (2005) · European Journal of Immunology · doi:10.1002/eji.200425405 · Cited by 696
François, M., Romieu-Mourez, R., Li, M., & Galipeau, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.189 · Cited by 694
English, K., Ryan, J. M., Tobin, L., Murphy, M. J., Barry, F. P., & Mahon, B. P. (2009) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2009.03874.x · Cited by 676
Rasmusson, I., Ringdén, O., Sundberg, B., & Le Blanc, K. (2003) · Transplantation · doi:10.1097/01.tp.0000082540.43730.80 · Cited by 663
The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells.
Ma, X., Chow, J. M., Gri, G., Carra, G., Gerosa, F., Wolf, S. F., Dzialo, R., & Trinchieri, G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.1.147 · Cited by 648
Ghannam, S., Pène, J., Torcy-Moquet, G., Jorgensen, C., & Yssel, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902007 · Cited by 597
Maccario, R., Podestà, M., Moretta, A., Cometa, A. M., Comoli, P., Montagna, D., Daudt, L. E., Ibatici, A., Piaggio, G., Pozzi, S., et al. (2005) · PubMed · Cited by 580
Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair
Shi, Y., Hu, G., Su, J., Li, W., Chen, Q., Shou, P., Xu, C., Chen, X., Huang, Y., Zhu, Z., et al. (2010) · Cell Research · doi:10.1038/cr.2010.44 · Cited by 575
Immunoregulatory function of mesenchymal stem cells
Uccelli, A., Moretta, L., & Pistoia, V. (2006) · European Journal of Immunology · doi:10.1002/eji.200636416 · Cited by 557
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications
Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C., & Noël, D. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt2 · Cited by 507 · cited 3×
“Introduction Mesenchymal stem cells (MSCs) are multipotential nonhematopoietic stem cells that possess the ability to selfrenew and to differentiate in response to chemical, hormonal or structural stimuli into different lineages of mesenchymal tissues, such as osteocytes, chondrocytes, neurocytes and adipocytes [1-7].”
BackgroundRASMUSSON, I., RINGDEN, O., SUNDBERG, B., & LEBLANC, K. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.12.013 · Cited by 493
Liotta, F., Angeli, R., Cosmi, L., Filì, L., Manuelli, C., Frosali, F., Mazzinghi, B., Maggi, L., Pasini, A., Lisi, V., et al. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0454 · Cited by 485
Prasanna, S. J., Gopalakrishnan, D., Shankar, S. R., & Vasandan, A. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009016 · Cited by 467
Immunomodulation by Mesenchymal Stem Cells
Abdi, R., Fiorina, P., Adra, C. N., Atkinson, M., & Sayegh, M. H. (2008) · Diabetes · doi:10.2337/db08-0180 · Cited by 463
Mesenchymal stem cell effects on T-cell effector pathways
Duffy, M. M., Ritter, T., Ceredig, R., & Griffin, M. D. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt75 · Cited by 430
Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues
Yoo, K. H., Jang, I. K., Lee, M. W., Kim, H. E., Yang, M. S., Eom, Y., Lee, J. E., Kim, Y. J., Yang, S. K., Jung, H. L., et al. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.06.010 · Cited by 416
Bouffi, C., Bony, C., Courties, G., Jorgensen, C., & Noël, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014247 · Cited by 383
Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction
Prevosto, C., Zancolli, M., Canevali, P., Zocchi, M. R., & Poggi, A. (2007) · Haematologica · doi:10.3324/haematol.11240 · Cited by 368
Patel, S. A., Meyer, J. R., Greco, S. J., Corcoran, K. E., Bryan, M., & Rameshwar, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903143 · Cited by 363
Immunosuppressive Effects of Mesenchymal Stem Cells: Involvement of HLA-G
Nasef, A., Mathieu, N., Chapel, A., Frick, J., François, S., Mazurier, C., Boutarfa, A., Bouchet, S., Gorin, N.-C., Thierry, D., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000267918.07906.08 · Cited by 350
Mesenchymal stem cells suppress B-cell terminal differentiation
Asari, S., Itakura, S., Ferreri, K., Liu, C.-P., Kuroda, Y., Kandeel, F., & Mullen, Y. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.01.005 · Cited by 342
Damle, R. N. (2002) · Blood · doi:10.1182/blood.v99.11.4087 · Cited by 341
Hayes, M., Wang, J., & Norcross, M. (1995) · Blood · doi:10.1182/blood.v86.2.646.bloodjournal862646 · Cited by 329
Le Blanc, K., Rasmusson, I., Götherström, C., Seidel, C., Sundberg, B., Sundin, M., Rosendahl, K., Tammik, C., & Ringdén, O. (2004) · Scandinavian Journal of Immunology · doi:10.1111/j.0300-9475.2004.01483.x · Cited by 329
dos Santos, F., Andrade, P. Z., Boura, J. S., Abecasis, M. M., da Silva, C. L., & Cabral, J. M. S. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.21987 · Cited by 314
Self-citationImmunological Aspects of Allogeneic Mesenchymal Stem Cell Therapies
Griffin, M. D., Ritter, T., & Mahon, B. P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.156 · Cited by 289
Tabera, S., Perez-Simon, J. A., Diez-Campelo, M., Sanchez-Abarca, L. I., Blanco, B., Lopez, A., Benito, A., Ocio, E., Sanchez-Guijo, F. M., Canizo, C., et al. (2008) · Haematologica · doi:10.3324/haematol.12857 · Cited by 283
Mesenchymal Stem Cells Stimulate Antibody Secretion in Human B Cells
Rasmusson, I., Le Blanc, K., Sundberg, B., & Ringdén, O. (2007) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2007.01905.x · Cited by 281
Najar, M., Raicevic, G., Boufker, H. I., Kazan, H. F., Bruyn, C. D., Meuleman, N., Bron, D., Toungouz, M., & Lagneaux, L. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.06.006 · Cited by 275
Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells
Chiesa, S., Morbelli, S., Morando, S., Massollo, M., Marini, C., Bertoni, A., Frassoni, F., Bartolomé, S. T., Sambuceti, G., Traggiai, E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103650108 · Cited by 269
Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells
Gieseke, F., Böhringer, J., Bussolari, R., Dominici, M., Handgretinger, R., & Müller, I. (2010) · Blood · doi:10.1182/blood-2010-02-270777 · Cited by 265
Hoskin, D., Mader, J., Furlong, S., Conrad, D., & Blay, J. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.527 · Cited by 242
Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10
Yang, S.-H., Park, M.-J., Yoon, I.-H., Kim, S.-Y., Hong, S.-H., Shin, J.-Y., Nam, H.-Y., Kim, Y.-H., Kim, B., & Park, C.-G. (2009) · Experimental and Molecular Medicine · doi:10.3858/emm.2009.41.5.035 · Cited by 241
Immunomodulatory Properties of Mesenchymal Stem Cells: Cytokines and Factors
Soleymaninejadian, E., Pramanik, K., & Samadian, E. (2012) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2011.01069.x · Cited by 239
Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation
Kolf, C. M., Cho, E., & Tuan, R. S. (2007) · Cited by 238
Rafei, M., Hsieh, J., Fortier, S., Li, M., Yuan, S., Birman, E., Forner, K., Boivin, M.-N., Doody, K., Tremblay, M., et al. (2008) · Blood · doi:10.1182/blood-2008-07-166892 · Cited by 224
Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study
Jiang, R., Han, Z., Zhuo, G., Qu, X., Li, X., Wang, X., Shao, Y., Yang, S., & Han, Z. C. (2011) · Frontiers of Medicine · doi:10.1007/s11684-011-0116-z · Cited by 218
Simms, P. E., & Ellis, T. M. (1996) · Clinical Diagnostic Laboratory Immunology · doi:10.1128/cdli.3.3.301-304.1996 · Cited by 206
Mesenchymal stem cells in immunoregulation
Chen, X., Armstrong, M. A., & Li, G. (2006) · Immunology & Cell Biology · doi:10.1111/j.1440-1711.2006.01458.x · Cited by 206
Schena, F., Gambini, C., Gregorio, A., Mosconi, M., Reverberi, D., Gattorno, M., Casazza, S., Uccelli, A., Moretta, L., Martini, A., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27560 · Cited by 202
Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway
Luz-Crawford, P., Noël, D., Fernandez, X., Khoury, M., Figueroa, F., Carrión, F., Jorgensen, C., & Djouad, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045272 · Cited by 195
Häusler, S. F. M., Montalbán del Barrio, I., Strohschein, J., Anoop Chandran, P., Engel, J. B., Hönig, A., Ossadnik, M., Horn, E., Fischer, B., Krockenberger, M., et al. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1040-4 · Cited by 193
Ramasamy, R., Tong, C. K., Seow, H. F., Vidyadaran, S., & Dazzi, F. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2008.04.009 · Cited by 191
Immune regulation by mesenchymal stem cells: two sides to the coin
Stagg, J. (2007) · Tissue Antigens · doi:10.1111/j.1399-0039.2006.00739.x · Cited by 189
Najar, M., Rouas, R., Raicevic, G., Boufker, H. I., Lewalle, P., Meuleman, N., Bron, D., Toungouz, M., Martiat, P., & Lagneaux, L. (2009) · Cytotherapy · doi:10.1080/14653240903079377 · Cited by 188
Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells
Chen, P.-M., Yen, M.-L., Liu, K.-J., Sytwu, H.-K., & Yen, B.-L. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-49 · Cited by 180
Yañez, R., Oviedo, A., Aldea, M., Bueren, J. A., & Lamana, M. L. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.08.008 · Cited by 177
Immunomodulatory Effect of Mesenchymal Stem Cells on B Cells
Franquesa, M., Hoogduijn, M. J., Bestard, O., & Grinyó, J. M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00212 · Cited by 175
Cutler, A. J., Limbani, V., Girdlestone, J., & Navarrete, C. V. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002239 · Cited by 170
Bochev, I., Elmadjian, G., Kyurkchiev, D., Tzvetanov, L., Altankova, I., Tivchev, P., & Kyurkchiev, S. (2008) · Cell Biology International · doi:10.1016/j.cellbi.2007.12.007 · Cited by 166
Semaphorin-3A is expressed by tumor cells and alters T-cell signal transduction and function
Catalano, A., Caprari, P., Moretti, S., Faronato, M., Tamagnone, L., & Procopio, A. (2006) · Blood · doi:10.1182/blood-2005-06-2445 · Cited by 165
Kronsteiner, B., Wolbank, S., Peterbauer, A., Hackl, C., Redl, H., van Griensven, M., & Gabriel, C. (2011) · Stem Cells and Development · doi:10.1089/scd.2011.0031 · Cited by 158
Mesenchymal Stem Cells – Sources and Clinical Applications
Klingemann, H., Matzilevich, D., & Marchand, J. (2008) · Transfusion Medicine and Hemotherapy · doi:10.1159/000142333 · Cited by 158
Giuliani, M., Oudrhiri, N., Noman, Z. M., Vernochet, A., Chouaib, S., Azzarone, B., Durrbach, A., & Bennaceur-Griscelli, A. (2011) · Blood · doi:10.1182/blood-2010-12-325324 · Cited by 158
Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation
Comoli, P., Ginevri, F., Maccario, R., Avanzini, M. A., Marconi, M., Groff, A., Cometa, A. M., Cioni, M., Porretti, L., Barberi, W., et al. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm740 · Cited by 151
Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Muller, A. J., & Prendergast, G. C. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780006896 · Cited by 148
Saldanha‐Araújo, F., Ferreira, F. I. S., Palma, P. V. B., Araújo, A. G., Queiróz, R. H. C., Covas, D. T., Zago, M. A., & Panepucci, R. A. (2011) · Stem Cell Research · doi:10.1016/j.scr.2011.04.001 · Cited by 144
Fu, Q., Chow, Y. Y., Sun, S., Zeng, Q., Li, H., Shi, J., Sun, Y., Wen, W., Tse, H., Lian, Q., et al. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02875.x · Cited by 143
Rea, I. M., McNerlan, S., & Alexander, H. D. (1999) · Experimental Gerontology · doi:10.1016/s0531-5565(98)00058-8 · Cited by 129
Sioud, M., Mobergslien, A., Boudabous, A., & Fløisand, Y. (2010) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2010.02378.x · Cited by 123
Bobis‐Wozowicz, S., Miękus, K., Wybieralska, E., Jarocha, D. J., Zawisz, A., Madeja, Z., & Majka, M. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.03.004 · Cited by 119
Najar, M., Raicevic, G., Boufker, H. I., Fayyad‐Kazan, H., Bruyn, C. D., Meuleman, N., Bron, D., Toungouz, M., & Lagneaux, L. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2010.0159 · Cited by 117
DelaRosa, O., Sánchez-Correa, B., Morgado, S., Ramírez, C., del Río, B., Menta, R., Lombardo, E., Tarazona, R., & Casado, J. G. (2011) · Stem Cells and Development · doi:10.1089/scd.2011.0139 · Cited by 109
Lepelletier, Y., Lecourt, S., Renand, A., Arnulf, B., Vanneaux, V., Fermand, J., Menasché, P., Domet, T., Marolleau, J., Hermine, O., et al. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0212 · Cited by 108
Yen, B. L., Chang, C. J., Liu, K., Chen, Y. C., Hu, H.-I., Bai, C.-H., & Yen, M. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0390 · Cited by 108
Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand?
Bassi, Ê. J., Aita, C. A. M., & CAMARA, N. O. S. (2011) · World Journal of Stem Cells · doi:10.4252/wjsc.v3.i1.1 · Cited by 105
Differentiation potential of mesenchymal stem cells of different origin
Musina, R. A., Bekchanova, E. S., Belyavsky, A. V., & Sukhikh, G. T. (2006) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-006-0115-2 · Cited by 102
Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation
Tatara, R., Ozaki, K., Kikuchi, Y., Hatanaka, K., Oh, I., Meguro, A., Matsu, H., Sato, K., & Ozawa, K. (2010) · Cytotherapy · doi:10.3109/14653249.2010.542456 · Cited by 101
Adult stem cells in the treatment of autoimmune diseases
van Laar, J. M., & Tyndall, A. (2006) · Rheumatology · doi:10.1093/rheumatology/kel158 · Cited by 101
Cooper, D. A., & Pellis, N. R. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.63.5.550 · Cited by 97
Long-Lasting Inhibitory Effects of Fetal Liver Mesenchymal Stem Cells on T-Lymphocyte Proliferation
Giuliani, M., Fleury, M., Vernochet, A., Ketroussi, F., Clay, D., Azzarone, B. G., Lataillade, J., & Dürrbach, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019988 · Cited by 94
Xue, Q., Luan, X.-Y., Gu, Y.-Z., Wu, H.-Y., Zhang, G.-B., Yu, G.-H., Zhu, H.-T., Wang, M., Dong, W., Geng, Y., et al. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0076 · Cited by 88
Inhibition of human B cell responsiveness by prostaglandin E2.
Simkin, N. J., Jelinek, D. F., & Lipsky, P. E. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.4.1074 · Cited by 85
Najar, M., Raicevic, G., Jebbawi, F., Bruyn, C. D., Meuleman, N., Bron, D., Toungouz, M., & Lagneaux, L. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.04.017 · Cited by 83
Engela, A. U., Baan, C. C., Dor, F. J. M. F., Weimar, W., & Hoogduijn, M. J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00126 · Cited by 83
Carrión, F., Nova‐Lamperti, E., Luz, P., Apablaza, F., & Figueroa, F. E. (2010) · Immunology Letters · doi:10.1016/j.imlet.2010.09.006 · Cited by 82
Spaggiari, G. M., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.03.133 · Cited by 81
Najar, M., Raicevic, G., Boufker, H. I., Stamatopoulos, B., Bruyn, C. D., Meuleman, N., Bron, D., Toungouz, M., & Lagneaux, L. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.05.007 · Cited by 69
From fibroblast cells to cardiomyocytes: direct lineage reprogramming
Yang, L. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt42 · Cited by 68
Reinisch, A., & Strunk, D. (2009) · Journal of Visualized Experiments · doi:10.3791/1525 · Cited by 68
Martins, Á., Paiva, A. A., Morgado, J. M., Gomes, A., & Pais, M. L. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.01.059 · Cited by 68
Self-citationGuo, Z., Zheng, C., Chen, Z., Gu, D., Du, W., Ge, J., Han, Z., & Yang, R. (2009) · European Journal of Immunology · doi:10.1002/eji.200839070 · Cited by 68
Holmannová, D., Koláčková, M., Kondělková, K., Kunes, P., Krejsek, J., & Andrýs, C. (2012) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2015.68 · Cited by 67
Ma, X., Che, N., Gu, Z., Huang, J., Wang, D., Liang, J., Hou, Y., Gilkeson, G. S., Lu, L., & Sun, L. (2013) · Cell Transplantation · doi:10.3727/096368912x658692 · Cited by 66
Human umbilical cord mesenchymal stem cells and the treatment of spinal cord injury
Cao, F., & Feng, S. (2009) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.2009.02.021 · Cited by 62
B7-H4 Treatment of T Cells Inhibits ERK, JNK, p38, and AKT Activation
Wang, X., Hao, J., Metzger, D. L., Ao, Z., Chen, L., Ou, D., Verchere, C. B., Mui, A., & Warnock, G. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0028232 · Cited by 51
Huss, D. J., Winger, R. C., Cox, G. M., Guerau‐de‐Arellano, M., Yang, Y., Racke, M. K., & Lovett‐Racke, A. E. (2011) · European Journal of Immunology · doi:10.1002/eji.201141666 · Cited by 49
Wang, Z., Tang, X., Xu, W., Cao, Z., Sun, L., Li, W., Li, Q., Zou, P., & Zhao, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057470 · Cited by 46
Selleri, S., Dieng, M. M., Nicoletti, S., Louis, I., Beausejour, C. M., Deist, F. L., & Haddad, É. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0315 · Cited by 41
Poeta, G. D., Principe, M. I. D., Zucchetto, A., Luciano, F., Buccisano, F., Rossi, F. M., Bruno, A., Biagi, A., Bulian, P., Maurillo, L., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.052829 · Cited by 40
Ostanin, A. A., Petrovskiy, Y. L., Shevela, Е. Y., & Chernykh, E. R. (2011) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-011-1275-2 · Cited by 31
Saygılı, T., Akıncılar, S. C., Akgül, B., & Nalbant, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049252 · Cited by 20
Buravkova, L. B., Grigorieva, O. G., Andreeva, E. R., Andrianova, I. V., & Rylova, Y. V. (2011) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-011-1326-8 · Cited by 9
Polarization of T Lymphocytes Is Regulated by Mesenchymal Stem Cells in NZBWF1 and BALB/c Mice
Sun, L., Liang, J., Li, H., & Hou, Y. (2007) · International Journal of Molecular Sciences · doi:10.3390/i8050455 · Cited by 4
Cited by
Mesenchymal stem cells and immunomodulation: current status and future prospects
Gao, F., Chiu, S. M., Motan, D. A. L., Zhang, Z., Chen, L., Ji, H.-L., Tse, H.-F., Fu, Q.-L., & Lian, Q. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.327 · Cited by 1,121
Immunoregulation by Mesenchymal Stem Cells: Biological Aspects and Clinical Applications
Castro-Manrreza, M. E., & Montesinos, J. J. (2015) · Journal of Immunology Research · doi:10.1155/2015/394917 · Cited by 399
Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges
Bagno, L., Hatzistergos, K. E., Balkan, W., & Hare, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.009 · Cited by 337
El Omar, R., Beroud, J., Stoltz, J.-F., Menu, P., Velot, E., & Decot, V. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0664 · Cited by 330
Mattar, P., & Bieback, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00560 · Cited by 300
Metadata
- Authors
- Ribeiro, A., Laranjeira, P., Mendes, S., Velada, I., Leite, C., Andrade, P., Santos, F., Henriques, A., Grãos, M., Cardoso, C. M. P., Martinho, A., Pais, M. L., da Silva, C. L., Cabral, J., Trindade, H., & Paiva, A.
- Venue
- Stem Cell Research & Therapy
- Published
- 2013-10-15
- Volume
- 4
- Issue
- 5
- Pages
- 125-125
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W2104239016
- Cited by
- 266
- References
- 116
- FWCI
- 9.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.